Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:ABMD

Abiomed - ABMD Price Target & Analyst Ratings

$377.23
-0.85 (-0.22%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$377.01
$378.18
50-Day Range
$242.49
$378.08
52-Week Range
$219.85
$381.99
Volume
830,277 shs
Average Volume
473,455 shs
Market Capitalization
$17.01 billion
P/E Ratio
64.82
Dividend Yield
N/A
Price Target
$350.50

Abiomed Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$350.50
-7.09% Downside
High Prediction$388.00
Average Prediction$350.50
Low Prediction$300.00
TypeCurrent
11/28/21 to 11/28/22
1 Month Ago
10/29/21 to 10/29/22
3 Months Ago
8/30/21 to 8/30/22
1 Year Ago
11/28/20 to 11/28/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
6 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$350.50$315.83$311.25$363.75
Predicted Upside-7.09% Downside14.27% Upside7.01% Upside2.45% Upside
Get Abiomed Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.


ABMD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abiomed Stock vs. The Competition

TypeAbiomedMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside-7.18% Downside756.56% Upside13.64% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
535
67.04%
Underperform Votes
263
32.96%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
851
68.13%
Avg. Underperform Votes
398
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/2/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$235.00 ➝ $380.00+0.58%
11/2/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$355.00 ➝ $388.00+2.69%
11/1/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
11/1/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$350.00 ➝ $380.00+0.27%
10/12/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$300.00+22.43%
4/5/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$330.00+2.33%
2/4/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$345.00 ➝ $325.00+11.87%
7/13/2020OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePositive
5/27/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Marie Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
3/23/2020Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$240.00 ➝ $155.00+24.21%
(Data available from 11/28/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABMD Price Target - Frequently Asked Questions

What is Abiomed's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Abiomed stock is Hold based on the current 6 hold ratings and 1 buy rating for ABMD. The average twelve-month price prediction for Abiomed is $350.50 with a high price target of $388.00 and a low price target of $300.00. Learn more on ABMD's analyst rating history.

Do Wall Street analysts like Abiomed more than its competitors?

Analysts like Abiomed less than other Medical companies. The consensus rating for Abiomed is Hold while the average consensus rating for medical companies is Buy. Learn more on how ABMD compares to other companies.

Do MarketBeat users like Abiomed more than its competitors?

MarketBeat users like Abiomed more than other Medical companies. 67.04% of MarketBeat users gave Abiomed an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is Abiomed being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Abiomed's stock had 3 downgrades and 1 upgrade by analysts.

Does Abiomed's stock price have much upside?

According to analysts, Abiomed's stock has a predicted upside of 5.54% based on their 12-month price targets.

What analysts cover Abiomed?

Abiomed has been rated by Deutsche Bank Aktiengesellschaft, Mizuho, Morgan Stanley, Piper Sandler, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ABMD) was last updated on 11/28/2022 by MarketBeat.com Staff